Blume-Jensen Peter 4

What Happened

• Peter Blume-Jensen, President, CEO and a director of Acrivon Therapeutics (ACRV), had 14,265 shares disposed on 2026-02-21 as shares were withheld to satisfy tax withholding on vested restricted stock units (RSUs). The withholding was recorded at $1.53 per share for a total value of approximately $21,825. This was a tax-withholding/cashless disposition (routine), not an open-market sale.

Key Details

• Transaction date: 2026-02-21; per-share price used for withholding: $1.53; total value ≈ $21,825.
• Transaction code: F — tax withholding to satisfy mandatory tax obligations on vesting (see footnote F1).
• Shares owned after the withholding: not specified in the provided excerpt.
• Filing date: Form 4 filed 2026-02-24 (no timeliness flag provided in the excerpt).
• Footnotes: F1 confirms shares were withheld by the issuer for taxes. F2/F3 note certain securities are held by each spouse (Dr. Blume-Jensen and Dr. Kristina Masson) with mutual disclaimers of beneficial ownership except for pecuniary interest.

Context

• Tax-withholding dispositions are common when RSUs vest and generally reflect administrative settlement rather than a vote on company prospects. This transaction does not represent an open-market sale by the CEO.